Literature DB >> 22113311

A competitive cell growth assay for the detection of subtle effects of gene transduction on cell proliferation.

J J M Eekels1, A O Pasternak, A M Schut, D Geerts, R E Jeeninga, B Berkhout.   

Abstract

RNA interference (RNAi) is a sequence-specific gene silencing mechanism with therapeutic potential against many human pathogens. To obtain a durable therapeutic effect, stable transduction of target cells with for instance a lentiviral vector that expresses a short hairpin (shRNA) inducer of the RNAi pathway is necessary. Apart from the intended therapeutic effect, this treatment can induce negative effects on cell proliferation via off-target effects. A careful evaluation of the transduced cells is required to develop a safe gene therapy approach. Stably transduced cells are usually selected by expression of the enhanced green fluorescent protein (GFP) marker. In this study we show that the mixed transduction culture, containing both transduced GFP(+) and untransduced GFP(-) cells, can simply be passaged to score the GFP(+)/GFP(-) ratio by longitudinal flow cytometric analysis as a measure of the negative impact of the RNAi treatment on the cellular proliferation rate. We show that this assay is sensitive, easy to use and internally controlled for assessing subtle effects on cell proliferation of lentiviral transduction and transgene expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22113311     DOI: 10.1038/gt.2011.191

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  26 in total

1.  SHAPE-directed discovery of potent shRNA inhibitors of HIV-1.

Authors:  Justin T Low; Stefanie A Knoepfel; Joseph M Watts; Olivier ter Brake; Ben Berkhout; Kevin M Weeks
Journal:  Mol Ther       Date:  2012-02-07       Impact factor: 11.454

Review 2.  Selection of RNAi-based inhibitors for anti-HIV gene therapy.

Authors:  Stefanie A Knoepfel; Mireille Centlivre; Ying Poi Liu; Fatima Boutimah; Ben Berkhout
Journal:  World J Virol       Date:  2012-06-12

3.  The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy.

Authors:  E Herrera-Carrillo; B Berkhout
Journal:  Gene Ther       Date:  2015-02-26       Impact factor: 5.250

4.  A novel approach to block HIV-1 coreceptor CXCR4 in non-toxic manner.

Authors:  Ye Liu; Jieqiong Zhou; Ji-An Pan; Prudence Mabiala; Deyin Guo
Journal:  Mol Biotechnol       Date:  2014-10       Impact factor: 2.695

5.  Growth-promoting and tumourigenic activity of c-Myc is suppressed by Hhex.

Authors:  V Marfil; M Blazquez; F Serrano; J V Castell; R Bort
Journal:  Oncogene       Date:  2014-09-15       Impact factor: 9.867

6.  Silencing of HIV-1 by AgoshRNA molecules.

Authors:  E Herrera-Carrillo; A Harwig; B Berkhout
Journal:  Gene Ther       Date:  2017-05-29       Impact factor: 5.250

7.  MAP3K11 is a tumor suppressor targeted by the oncomiR miR-125b in early B cells.

Authors:  U Knackmuss; S E Lindner; T Aneichyk; B Kotkamp; Z Knust; A Villunger; S Herzog
Journal:  Cell Death Differ       Date:  2015-07-03       Impact factor: 15.828

8.  GLUT5 (SLC2A5) enables fructose-mediated proliferation independent of ketohexokinase.

Authors:  Roger J Liang; Samuel Taylor; Navid Nahiyaan; Junho Song; Charles J Murphy; Ezequiel Dantas; Shuyuan Cheng; Ting-Wei Hsu; Shakti Ramsamooj; Rahul Grover; Seo-Kyoung Hwang; Bryan Ngo; Lewis C Cantley; Kyu Y Rhee; Marcus D Goncalves
Journal:  Cancer Metab       Date:  2021-03-24

9.  Inhibition of HIV-1 replication with stable RNAi-mediated knockdown of autophagy factors.

Authors:  Julia Jm Eekels; Sophie Sagnier; Dirk Geerts; Rienk E Jeeninga; Martine Biard-Piechaczyk; Ben Berkhout
Journal:  Virol J       Date:  2012-03-16       Impact factor: 4.099

10.  The miR-26 family regulates early B cell development and transformation.

Authors:  Katharina Hutter; Silke E Lindner; Constanze Kurschat; Thomas Rülicke; Andreas Villunger; Sebastian Herzog
Journal:  Life Sci Alliance       Date:  2022-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.